IN2015DN04094A - - Google Patents
Info
- Publication number
- IN2015DN04094A IN2015DN04094A IN4094DEN2015A IN2015DN04094A IN 2015DN04094 A IN2015DN04094 A IN 2015DN04094A IN 4094DEN2015 A IN4094DEN2015 A IN 4094DEN2015A IN 2015DN04094 A IN2015DN04094 A IN 2015DN04094A
- Authority
- IN
- India
- Prior art keywords
- dimethyl
- trioxo
- pyrido
- pyrimidin
- tetrahydro
- Prior art date
Links
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- -1 fluoro 4 iodo phenylamino Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261731597P | 2012-11-30 | 2012-11-30 | |
| PCT/US2013/071816 WO2014085371A1 (en) | 2012-11-30 | 2013-11-26 | Novel pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN04094A true IN2015DN04094A (pl) | 2015-10-09 |
Family
ID=50828398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4094DEN2015 IN2015DN04094A (pl) | 2012-11-30 | 2013-11-26 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20150328320A1 (pl) |
| EP (2) | EP2925299B1 (pl) |
| JP (1) | JP6232443B2 (pl) |
| KR (1) | KR102206432B1 (pl) |
| CN (2) | CN104902876B (pl) |
| AR (1) | AR093648A1 (pl) |
| AU (1) | AU2013352369B2 (pl) |
| BR (1) | BR112015012111A8 (pl) |
| CA (1) | CA2891346A1 (pl) |
| CL (1) | CL2015001459A1 (pl) |
| EA (2) | EA201791411A1 (pl) |
| ES (1) | ES2686730T3 (pl) |
| IL (3) | IL300664A (pl) |
| IN (1) | IN2015DN04094A (pl) |
| MA (1) | MA38121A1 (pl) |
| MX (1) | MX2015006867A (pl) |
| MY (1) | MY170427A (pl) |
| NZ (1) | NZ628395A (pl) |
| PE (1) | PE20151024A1 (pl) |
| PH (1) | PH12015501168A1 (pl) |
| PL (1) | PL2925299T3 (pl) |
| PT (1) | PT2925299T (pl) |
| SG (1) | SG11201503688SA (pl) |
| TN (1) | TN2015000198A1 (pl) |
| TW (2) | TW201434468A (pl) |
| UY (1) | UY35157A (pl) |
| WO (1) | WO2014085371A1 (pl) |
| ZA (1) | ZA201503346B (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102293907B1 (ko) * | 2015-06-30 | 2021-08-26 | 한미약품 주식회사 | 이리노테칸 함유 경구용 고형제제 및 그 제조방법 |
| US20200178569A1 (en) * | 2016-04-29 | 2020-06-11 | Alvin Kershman | Method of Coating an Edible Thermoplastic Pet Chew |
| TW201818936A (zh) * | 2016-11-25 | 2018-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種吡啶酮類衍生物醫藥組成物及其製備方法 |
| KR102230721B1 (ko) * | 2019-02-01 | 2021-03-22 | 주식회사 오스코텍 | 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법 |
| CA3186465A1 (en) * | 2019-10-22 | 2021-04-29 | Chemistry Rx | Methods for treating congenital epidermal hyperplasia |
| WO2023113479A1 (en) * | 2021-12-15 | 2023-06-22 | Sillajen, Inc. | Pharmaceutical compositions comprising modified beta-cyclodextrins |
| KR20250008895A (ko) * | 2022-05-12 | 2025-01-16 | 주식회사 지뉴브 | 안정한 액상 제약 제제 |
| WO2025132408A2 (en) | 2023-12-21 | 2025-06-26 | Synthon B.V. | Solvates of trametinib |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6077871A (en) * | 1997-11-26 | 2000-06-20 | Pfizer Inc. | Droloxifene pharmaceutical compositions |
| US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| MXPA06014478A (es) | 2004-06-11 | 2007-03-21 | Japan Tobacco Inc | Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer. |
| ES2549763T3 (es) * | 2004-12-07 | 2015-11-02 | Onyx Therapeutics, Inc. | Composición para inhibición del proteasoma |
| CN1872055A (zh) * | 2005-06-01 | 2006-12-06 | 李�杰 | 适合儿童应用的阿莫西林与盐酸氨溴索的复方制剂及其处方和制备方法 |
| PL2952197T3 (pl) * | 2005-10-26 | 2017-09-29 | Cydex Pharmaceuticals, Inc. | Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania |
| US20080176946A1 (en) * | 2007-01-16 | 2008-07-24 | Bipar Sciences, Inc. | Formulations for cancer treatment |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| CN101352419B (zh) * | 2007-07-26 | 2010-08-11 | 天津药物研究院 | 一种醋溴茶碱无糖型颗粒剂及其制备方法 |
| KR101478779B1 (ko) * | 2007-11-22 | 2015-01-05 | 에스케이케미칼주식회사 | 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법 |
| SI2488033T1 (sl) | 2009-10-16 | 2019-10-30 | Novartis Ag | Kombinacija, ki vsebuje inhibitor MEK in inhibitor B-RAF |
| CN103370320B (zh) | 2010-11-11 | 2016-04-27 | 拜耳知识产权有限责任公司 | 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉 |
| TWI505828B (zh) * | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| US20130023531A1 (en) | 2011-01-27 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors |
| EP2680886B1 (en) | 2011-02-28 | 2016-08-10 | Calitor Sciences, LLC | Substituted quinoline compounds |
| SI2694510T1 (sl) * | 2011-04-07 | 2016-02-29 | Bayer Intellectual Property Gmbh | Imidazopiridazini kot inhibitorji AKT kinaze |
| CN102600132B (zh) * | 2012-03-13 | 2014-05-14 | 齐鲁制药有限公司 | 一种含氨磺必利的口服制剂 |
| CN102626394A (zh) * | 2012-03-15 | 2012-08-08 | 合肥科大生物技术有限公司 | 一种精氨酸布洛芬颗粒剂及其制备方法 |
-
2013
- 2013-11-26 SG SG11201503688SA patent/SG11201503688SA/en unknown
- 2013-11-26 IL IL300664A patent/IL300664A/en unknown
- 2013-11-26 IN IN4094DEN2015 patent/IN2015DN04094A/en unknown
- 2013-11-26 PL PL13857873T patent/PL2925299T3/pl unknown
- 2013-11-26 NZ NZ628395A patent/NZ628395A/en not_active IP Right Cessation
- 2013-11-26 PE PE2015000701A patent/PE20151024A1/es not_active Application Discontinuation
- 2013-11-26 BR BR112015012111A patent/BR112015012111A8/pt not_active IP Right Cessation
- 2013-11-26 MX MX2015006867A patent/MX2015006867A/es unknown
- 2013-11-26 WO PCT/US2013/071816 patent/WO2014085371A1/en not_active Ceased
- 2013-11-26 AU AU2013352369A patent/AU2013352369B2/en active Active
- 2013-11-26 CN CN201380062796.7A patent/CN104902876B/zh active Active
- 2013-11-26 EA EA201791411A patent/EA201791411A1/ru unknown
- 2013-11-26 PT PT13857873T patent/PT2925299T/pt unknown
- 2013-11-26 ES ES13857873.7T patent/ES2686730T3/es active Active
- 2013-11-26 JP JP2015545165A patent/JP6232443B2/ja active Active
- 2013-11-26 IL IL266415A patent/IL266415B2/en unknown
- 2013-11-26 EP EP13857873.7A patent/EP2925299B1/en not_active Revoked
- 2013-11-26 MA MA38121A patent/MA38121A1/fr unknown
- 2013-11-26 US US14/647,606 patent/US20150328320A1/en not_active Abandoned
- 2013-11-26 EP EP18173387.4A patent/EP3400933A1/en active Pending
- 2013-11-26 EA EA201591047A patent/EA028246B1/ru not_active IP Right Cessation
- 2013-11-26 CA CA2891346A patent/CA2891346A1/en not_active Abandoned
- 2013-11-26 MY MYPI2015001232A patent/MY170427A/en unknown
- 2013-11-26 KR KR1020157016931A patent/KR102206432B1/ko active Active
- 2013-11-26 CN CN201711343653.XA patent/CN107970214A/zh active Pending
- 2013-11-28 TW TW102143365A patent/TW201434468A/zh unknown
- 2013-11-28 TW TW106137040A patent/TW201831187A/zh unknown
- 2013-11-28 AR ARP130104392A patent/AR093648A1/es unknown
- 2013-11-28 UY UY0001035157A patent/UY35157A/es unknown
-
2015
- 2015-05-13 ZA ZA2015/03346A patent/ZA201503346B/en unknown
- 2015-05-21 IL IL238971A patent/IL238971B/en active IP Right Grant
- 2015-05-22 TN TNP2015000198A patent/TN2015000198A1/fr unknown
- 2015-05-26 PH PH12015501168A patent/PH12015501168A1/en unknown
- 2015-05-29 CL CL2015001459A patent/CL2015001459A1/es unknown
-
2017
- 2017-03-07 US US15/451,888 patent/US20170189408A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN04094A (pl) | ||
| JOP20190041A1 (ar) | مركبات وتركيبات كمثبطات لمستقبلات شبيهة بالتول إندوسومية | |
| JO3594B1 (ar) | تركيبة صيدلانية جديدة | |
| MY179392A (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| MY193728A (en) | Muscarinic receptor agonists | |
| MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| GEP20156217B (en) | 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors | |
| PH12015501779A1 (en) | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak) | |
| PH12015502780B1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| UY36265A (es) | “derivados de pirrolo[2,3-d]pirimidina”. | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| PH12017501816B1 (en) | Azabenzimidazoles and their use as ampa receptor modulators | |
| IN2014CN03597A (pl) | ||
| TW201613864A (en) | Novel compounds | |
| MY169268A (en) | Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5-disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases | |
| MX2015012896A (es) | Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa. | |
| PH12016501686A1 (en) | Pharmaceutical compositions of sitagliptin | |
| IN2014DN10691A (pl) | ||
| GEP20186909B (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
| PH12018502139A1 (en) | Phosphaplatin liquid formulations | |
| IN2015DN02109A (pl) | ||
| NZ778505A (en) | Crystalline form of lorlatinib free base |